[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Kumar M, Bahl A, Sharma DN, Sharma R, Gupta R, Ahmed S, Julka PK, Rath GK: Cylindric cell carcinoma of the base of the tongue: a rare variant of squamous cell carcinoma. J Cancer Res Ther; 2009 Apr-Jun;5(2):124-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cylindric cell carcinoma of the base of the tongue: a rare variant of squamous cell carcinoma.
  • Cylindric cell carcinomas (transitional cell carcinomas) are a rare and distinct histopathological entity presenting in the head and neck region.
  • They have been known by myriads of nomenclature like cylindric carcinomas, nonkeratinizing sinonasal carcinoma, papillary carcinoma, cylindrical or columnar cell carcinoma, intermediate cell carcinoma, Schneiderian carcinoma, and Ringertz carcinoma.
  • They are considered a variant of nonkeratinizing squamous cell carcinoma.
  • Cylindric carcinomas are usually described in the sinus and nasal cavity and rarely said to involve nasopharynx and larynx.
  • We report here a rare case of transitional cell carcinoma presenting in the base of the tongue.
  • There are no separate treatment recommendations in the literature, and the management is on the lines of treatment of squamous cell carcinoma.
  • We report here a case of cylindric cell carcinoma presenting in the base of the tongue.
  • The patient received palliative radiotherapy of 20 Gy in five fractions followed by chemotherapy with injection paclitaxel and carboplatin.
  • A partial response to treatment was achieved at the time of writing this report.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542670.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Lee HL, Ahn MJ, Choi JH, Jun WH, Lee YY, Kim IS, Choi IY, Jang SJ, Park YW: A case of NK/T-cell lymphoma complicated by a squamous cell carcinoma of hard palate during combination chemotherapy and radiation therapy. Korean J Intern Med; 2002 Mar;17(1):69-72
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of NK/T-cell lymphoma complicated by a squamous cell carcinoma of hard palate during combination chemotherapy and radiation therapy.
  • NK/T-cell lymphoma, which often shows an angiocentric growth pattern, is a distinct clinicopathologic entity highly associated with Epstein-Barr virus.
  • The disease is characterized by a destruction of the upper respiratory tract, particularly the nasal cavity, palate and paranasal sinuses.
  • Interestingly, NK/T-cell lymphoma is closely linked to a variety of complications, such as hemophagocytic syndrome, second primary cancer, sepsis and bleeding.
  • Here we report a case of a 50-year-old man diagnosed initially as NK/T-cell lymphoma of the oropharynx and who developed a second primary carcinoma of the hard palate during combination chemotherapy and radiation therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / pathology. Oropharyngeal Neoplasms / pathology. Palatal Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Humans. Killer Cells, Natural. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12014217.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC4531653
  •  go-up   go-down


3. Brennan B: Nasopharyngeal carcinoma. Orphanet J Rare Dis; 2006;1:23
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal carcinoma.
  • Nasopharyngeal carcinoma (NPC) is a tumor arising from the epithelial cells that cover the surface and line the nasopharynx.
  • 1) squamous cell carcinoma, typically found in the older adult population;.
  • 2) non-keratinizing carcinoma;.
  • 3) undifferentiated carcinoma.
  • The tumor can extend within or out of the nasopharynx to the other lateral wall and/or posterosuperiorly to the base of the skull or the palate, nasal cavity or oropharynx.
  • Cervical lymphadenopathy is the initial presentation in many patients, and the diagnosis of NPC is often made by lymph node biopsy.
  • Symptoms related to the primary tumor include trismus, pain, otitis media, nasal regurgitation due to paresis of the soft palate, hearing loss and cranial nerve palsies.
  • Larger growths may produce nasal obstruction or bleeding and a "nasal twang".
  • The recommended treatment schedule consists of three courses of neoadjuvant chemotherapy, irradiation, and adjuvant interferon (IFN)-beta therapy.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / diagnosis. Child. Child, Preschool. Global Health. Humans. Incidence. Infant. Infant, Newborn. Neoplasm Staging / methods. Prognosis. Radiotherapy / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Mar;41(3):1128-33 [638955.001]
  • [Cites] IARC Sci Publ. 1978;(20):115-29 [730188.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Apr;6(4):487-91 [7390929.001]
  • [Cites] Cancer. 1981 Jan 15;47(2):360-6 [7459824.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):163-9 [7053813.001]
  • [Cites] Med Pediatr Oncol. 1982;10(3):243-50 [7087893.001]
  • [Cites] Int J Cancer. 1983 Aug 15;32(2):171-6 [6874140.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1984 Sep-Oct;93(5 Pt 1):477-82 [6093669.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):956-61 [3940655.001]
  • [Cites] J Laryngol Otol. 1987 Dec;101(12):1248-53 [3323380.001]
  • [Cites] Int J Cancer. 1988 Aug 15;42(2):176-81 [2841245.001]
  • [Cites] Pediatr Hematol Oncol. 1986;3(2):143-52 [3153224.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4003-6 [8033130.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jun;3(4):305-10 [8061578.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1357-60 [8067705.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1188-91 [10096545.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):850-7 [15641027.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):1083-9 [15999363.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5452-5 [10554016.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2351-5 [10811107.001]
  • [Cites] J Pediatr. 1974 Jan;84(1):96-100 [12119964.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]
  • [Cites] Arch Surg. 1967 Feb;94(2):214-7 [6016269.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • [Cites] Laryngoscope. 1972 May;82(5):807-16 [4337403.001]
  • [Cites] Nat New Biol. 1973 Aug 22;244(138):245-7 [4353684.001]
  • [Cites] J Pediatr. 1975 Feb;86(2):254-8 [1111694.001]
  • [Cites] Int J Cancer. 1975 Apr 15;15(4):651-7 [1173575.001]
  • (PMID = 16800883.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  • [Other-IDs] NLM/ PMC1559589
  • [General-notes] NLM/ Original DateCompleted: 20070719
  •  go-up   go-down


Advertisement
4. Paulino AF, Singh B, Carew J, Shah JP, Huvos AG: Epstein-Barr virus in squamous carcinoma of the anterior nasal cavity. Ann Diagn Pathol; 2000 Feb;4(1):7-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus in squamous carcinoma of the anterior nasal cavity.
  • Squamous carcinoma is the most common malignancy of the head and neck, but it rarely occurs in the nasal vestibule.
  • Epstein-Barr virus (EBV) has been detected in and is causally linked to various head and neck tumors, particularly nasopharyngeal carcinoma.
  • The possible role of EBV in squamous carcinoma of the anterior nasal cavity, particularly of the nasal vestibule, has not been previously investigated.
  • Histologic sections from 17 patients with nasal vestibular squamous carcinoma were examined.
  • Material for EBV detection by immunohistochemistry and by in situ hybridization was available in 15 of the 17 cases.
  • The squamous carcinomas were graded as well differentiated (one case), moderately differentiated (11 cases), and poorly differentiated (five cases).
  • Treatment modalities included surgical resection, radiation, chemotherapy, or a combined approach.
  • Three patients developed metastases, one of whom died of disease after 1 year.
  • Squamous carcinoma of the nasal vestibule is an uncommon cancer that is not causally related to EBV.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Herpesvirus 4, Human / isolation & purification. Nasal Cavity / virology. Nose Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10684374.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


5. Jang NY, Wu HG, Park CI, Heo DS, Kim DW, Lee SH, Rhee CS: Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity. Jpn J Clin Oncol; 2010 Jun;40(6):542-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity.
  • OBJECTIVE: To evaluate the efficacy and toxicity of definitive radiotherapy with or without chemotherapy for T3-4 squamous cell carcinoma of maxillary sinus and nasal cavity.
  • METHODS: Forty-two patients with T3-4N0 squamous cell carcinoma of maxillary sinus (n = 30) and nasal cavity (n = 12) received definitive radiotherapy.
  • Chemotherapy was used in 34 patients and elective neck irradiation was not used.
  • RESULTS: The 5-year overall survival/local control rates were 34%/29% for maxillary sinus cancer and 50%/52% for nasal cavity cancer.
  • For maxillary sinus cancers, a performance status of Eastern Cooperative Oncology Group >or=2 (P = 0.012), biologically equivalent dose <68 Gy (P = 0.011) and no use of chemotherapy (P = 0.037) were significant worse predictors for overall survival on log-rank analysis.
  • Biologically equivalent dose <68 Gy was independently associated with poor local control (hazard ratio, 3.32; 95% confidence interval, 1.38-7.97; P = 0.007) and overall survival (hazard ratio, 2.94; 95% confidence interval, 1.23-7.01; P = 0.015).
  • Regional recurrence occurred in only 1 of 30 patients with maxillary sinus cancer and 4 of 12 patients with nasal cavity.
  • CONCLUSIONS: The treatment outcome was poor and local control was a major problem.
  • High radiation dose, effective chemotherapy and elective neck irradiation for advanced nasal cavity cancers may improve disease control.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Maxillary Sinus Neoplasms / radiotherapy. Nasal Cavity. Nose Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Palliative Care. Prognosis. Radiation Injuries. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185459.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


6. Ng W, Jacob S, Delaney G, Barton M: Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care. Eur J Cancer; 2009 Aug;45(12):2150-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care.
  • BACKGROUND: We estimated the optimal chemotherapy utilisation rate for head and neck cancer as a benchmark for measuring and improving the quality of cancer care.
  • METHODS: An optimal chemotherapy utilisation tree was constructed using indications for chemotherapy that were identified from evidence-based treatment guidelines.
  • Data on the proportion of patient and tumour-related attributes for which chemotherapy was indicated were obtained and merged with the treatment indications to calculate the optimal utilisation rate.
  • The optimal chemotherapy utilisation rate was compared with actual utilisation rates reported.
  • RESULTS: Chemotherapy is indicated at least once in 36% (95% CI, 33-38%) of all patients with head and neck carcinoma.
  • The optimal utilisation rates by subsites were as follows: lip, 8%; oral cavity, 40%; nasopharynx, 69%; oropharynx, 66%; hypopharynx, 74%; larynx, 43%; salivary gland, 48% and paranasal sinus with nasal cavity, 38%.
  • CONCLUSIONS: The optimal proportion of patients who should receive chemotherapy in the head and neck carcinoma population has risen significantly over the past 20 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19285857.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


7. Daele JJ, Vander Poorten V, Rombaux P, Hamoir M: Cancer of the nasal vestibule, nasal cavity and paranasal sinuses. B-ENT; 2005;Suppl 1:87-94; quiz 95-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the nasal vestibule, nasal cavity and paranasal sinuses.
  • The usual clinical presentation of sinonasal tumours includes symptoms that are indistinguishable from inflammatory sinus disease, namely nasal airway obstruction, pain, and epistaxis.
  • Computed tomography is the most reliable and informative imaging tool for evaluating the cancers of the paranasal sinuses.
  • Magnetic resonance imaging is essential for tumour mapping because of the excellent tissue characterisation and the possibility of differentiating between neoplasms and retained secretions.
  • A wide variety of histologies may be encountered, although squamous cell carcinoma (SCCA) is the most common.
  • The response of sinonasal tract tumours to radiation therapy varies with the stage and histology of the tumour.
  • Management of these tumours requires a multimodal approach, involving surgery, radiation therapy and, increasingly in recent years, chemotherapy.
  • [MeSH-major] Nasal Cavity / pathology. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363270.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 49
  •  go-up   go-down


8. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck; 2002 Sep;24(9):821-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumors of the nasal cavity and paranasal sinuses.
  • PURPOSE: To evaluate the role of radiation therapy in patients with nasal cavity and paranasal sinus tumors.
  • MATERIALS AND METHODS: Between October 1964 and July 1998, 78 patients with malignant tumors of the nasal cavity (48 patients), ethmoid sinus (24 patients), sphenoid sinus (5 patients), or frontal sinus (1 patient) were treated with curative intent by radiation therapy alone or in the adjuvant setting.
  • There were 25 squamous cell carcinomas, 14 undifferentiated carcinomas, 31 minor salivary gland tumors (adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma), 8 esthesioneuroblastomas, and 1 transitional cell carcinoma.
  • Forty-seven patients were treated with irradiation alone, 25 with surgery and postoperative irradiation, 2 with preoperative irradiation and surgery, and 4 with chemotherapy in combination with irradiation with or without surgery.
  • Of the 67 (86%) patients who were initially seen with node-negative disease, 39 (58%) received no elective neck treatment, and 28 (42%) received elective neck irradiation.
  • Of the 39 patients who received no elective neck treatment, 33 (85%) did not experience recurrence in the neck compared with 25 (89%) of 28 patients who received elective neck irradiation.
  • CONCLUSION: Surgery and postoperative radiation therapy may result in improved local control, absolute survival, and complications when compared with radiation therapy alone.
  • [MeSH-major] Carcinoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blindness / etiology. Blindness / prevention & control. Cause of Death. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Osteoradionecrosis / etiology. Postoperative Care. Preoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 821-829, 2002
  • (PMID = 12211046.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Sato H, Murai K, Kanda T, Mimura R, Hiratsuka Y: Association of chromium exposure with multiple primary cancers in the nasal cavity. Auris Nasus Larynx; 2003 Feb;30(1):93-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of chromium exposure with multiple primary cancers in the nasal cavity.
  • A 56-year-old man who had worked at a chromate factory for 13 years developed squamous cell carcinoma of the left nasal cavity 11 years after retirement.
  • He received intra-arterial chemotherapy, followed by surgery.
  • Two years later, an adenocarcinoma was identified in the same nasal cavity just above the previous surgical region.
  • The present case seems to have resulted from long-term exposure to chromium and, to our knowledge, is the first reported case with multiple primary cancers in the nasal cavity associated with chromium exposure.
  • [MeSH-major] Adrenal Gland Neoplasms / chemically induced. Carcinoma, Squamous Cell / chemically induced. Chromium / adverse effects. Nasal Cavity / pathology. Neoplasms, Multiple Primary / chemically induced. Nose Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12589859.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0R0008Q3JB / Chromium
  •  go-up   go-down


10. Xiao W, Yi Z: [Combined therapy of advanced tonsillar squamous cell carcinoma and one-stage repair of the defect]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2002 Feb;37(1):41-3
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined therapy of advanced tonsillar squamous cell carcinoma and one-stage repair of the defect].
  • OBJECTIVE: To evaluate the treatment of advanced squamous cell carcinoma of the tonsil.
  • METHODS: Eight patients with advanced tonsillar carcinoma underwent resections combining mandibular ramus and oral cavity approaches, neck dissection and one-stage repair of the defect with pectoralis major myocutaneous flap (PM).
  • The managements were supplemented with preoperative chemotherapy and postoperative radiotherapy.
  • One case died of serious hemorrhage resulted from radio-mandibulomyelitis 3 months after operation, and the other case died of esophageal carcinoma 2 years after operation.
  • Two cases suffered from temporary regurgitation of food to the nasal chamber.
  • CONCLUSIONS: Through this combined approach, the advanced tonsillar carcinoma could be resected en bloc under direct visual field and keeping 1-1.5 cm safe margin to the tumor.
  • Neck dissection, preoperative chemotherapy and postoperative radiotherapy were supplemental measures.
  • Combined therapy was of great significance in reducing recurrence of the tumor.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Surgical Flaps. Tonsillar Neoplasms / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pectoralis Muscles / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12768794.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Baptista P, Garcia Velloso MJ, Salvinelli F, Casale M: Radioguided surgical strategy in mucosal melanoma of the nasal cavity. Clin Nucl Med; 2008 Jan;33(1):14-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioguided surgical strategy in mucosal melanoma of the nasal cavity.
  • Sinonasal mucosal melanoma (MM), although very rare (<1% of the all MM), is second only to squamous cell carcinoma among cancers of the nasal region and still represents a challenging problem in head and neck cancer.
  • A 60-year-old woman had nasal MM stage I, which was treated with concomitant probe-guided tumor excision and an elective neck dissection after sentinel lymph node biopsy.
  • The patient was seen in frequent and regular follow-up and was free of disease without any other treatment (radiotherapy, immunotherapy, or chemotherapy).
  • A multidisciplinary approach and further studies with a longer follow-up are needed to substantiate the accuracy and safety of this strategy in the treatment of an aggressive neoplasm like MM of the head and neck, which still has a very poor prognosis.
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Female. Gamma Cameras. Humans. Middle Aged. Radiosurgery. Sentinel Lymph Node Biopsy. Technetium Tc 99m Aggregated Albumin. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097249.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Technetium Tc 99m Aggregated Albumin; 0 / technetium Tc 99m nanocolloid
  •  go-up   go-down


12. Hu WH, Xie FY, Fang SH, Jiao JJ, Yan C, Peng WJ, Fu XY, Zhang F: [Cancer of the nasal cavity]. Zhonghua Zhong Liu Za Zhi; 2005 Feb;27(2):117-21
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer of the nasal cavity].
  • OBJECTIVE: To analyze the factors affecting prognosis of patients with nasal carcinoma.
  • The 5-year survival rate was 55.8% in squamous-cell carcinoma, 44.0% in adenocarcinoma, 59.7% in undifferentiated carcinoma, 76.3% in adenoid cystic carcinoma, 71.4% in mucoepidermoid carcinoma, 25.0% in rhabdomyosarcoma, 26.7% in malignant melanoma, 50.0% in neuroblastoma (P > 0.05).
  • The 5-year survival rate was 73.8% in patients whose cancer completely disappeared after treatment.
  • That with chemotherapy only was 25.0% whereas that of patients treated with combination treatment was 61.8% (P > 0.05).
  • CONCLUSION: Clinical stage, immediate therapeutic response and involvement of sphenoidal or maxillary sinus; but not the pathologic type, the presence of cervical metastasis nor the method of treatment, are the factors affecting the prognosis of patients with nasal carcinoma.
  • [MeSH-major] Nasal Cavity. Nose Neoplasms / mortality. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946555.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


13. Diba R, Saadati HG, Esmaeli B: Outcomes of dacrocystorhinostomy in patients with head and neck tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):5584

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor diagnoses were as follows: squamous cell carcinoma (SCCA), 18 patients (16 had paranasal-sinus SCCA and 2 had skin SCCA); chondrosarcoma, 3; sinonasal carcinoma, 2; adenoid cystic carcinoma, 2; sinonasal papilloma, 2; esthesioneuroblastoma, 1; hemangiopericytoma,1; ameloblastoma,1; and ostoesarcoma,1.
  • Six patients had had silicone intubation at the time of maxillectomy but later developed epiphora and nasolacrimal duct blockage.
  • Ten patients had radiotherapy and 14 had chemotherapy and radiotherapy before DCR.
  • The mean time between completion of radiotherapy and DCR was 24 months (median, 31.5 months), and the mean time between completion of chemotherapy and DCR was 21.5 months (median, 12.5 months).
  • In 1 of these 4 patients, tumor recurrence in the nasal cavity was the cause; he subsequently underwent a total rhinectomy.
  • None of the patients who had had radiotherapy developed osteoradionecrosis.
  • Two patients had mild wound infections, which resolved after 1 week of systemic antibiotic therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014063.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Hameed S, Jamshed A, Hussain R, Ali M, Iqbal H, Majeed U, Shah MA: Neoadjuvant chemotherapy followed by radiotherapy or chemoradiation for locally advanced nasal and paranasal sinus tumors. J Clin Oncol; 2009 May 20;27(15_suppl):6055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by radiotherapy or chemoradiation for locally advanced nasal and paranasal sinus tumors.
  • : 6055 Background: The treatment of locally advanced nasal and paranasal sinus tumors is controversial.
  • The disease is chemosensitive and there is increasing interest in the use of chemotherapy with radiation in this group of patients.
  • Our aim was to determine survival in patients with locally advanced nasal and paranasal sinus tumors treated with neoadjuvant chemotherapy followed by radiotherapy or chemoradiation (RT/CRT).
  • METHODS: Between August 2005 and August 2008, 21 patients with AJCC stage III or IV nasal and paranasal sinus tumors were treated with neoadjuvant chemotherapy followed by RT/CRT in our institution.
  • There were 15 males and 6 females (M 71%:F 29%) with a median age of 49 years (range 19 - 70 years).
  • Site of disease was nasal cavity 33% (7), ethamoid sinus 43% (9), maxillary antrum 19% (4), and frontal sinus in 5% (1) of patients.
  • Histopathological diagnosis was squamous cell carcinoma 43% (9), undifferentiated carcinoma 29% (6), adenocarcinoma 19% (4), esthesioneuroblastoma in 9% (2) of patients.
  • Induction chemotherapy consisted of cisplatin 75 mg / metre<sup>2</sup> day 1 and gemcitabine 1 gm / metre<sup>2</sup> day 1 and 8 every three weeks.
  • Eighty-five percent (18/21) received 2 cycles of neoadjuvant chemotherapy (range 1-4 cycles) prior to radiotherapy.
  • Radiotherapy dose was 54 Gy - 70 Gy (median radiation dose 66 Gy).
  • RESULTS: Response to neoadjuvant chemotherapy; complete in 19% (4), partial in 67% (14), no response/progression 14% (3).
  • Thirty-three percent (7/21) have failed treatment (local 3, regional 2, and distant metastasis in 2 patients).
  • Among treatment failures 2 patients were successfully salvaged; surgery for local recurrence in one patient and in the other case radiation was given for regional recurrence.
  • CONCLUSIONS: Gemcitabine cisplatin chemotherapy has good activity in nasal and paranasal sinus tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961932.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Chen AM, Daly ME, Bucci MK, Xia P, Akazawa C, Quivey JM, Weinberg V, Garcia J, Lee NY, Kaplan MJ, El-Sayed I, Eisele DW, Fu KK, Phillips TL: Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):141-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?
  • PURPOSE: To compare clinical outcomes of patients with carcinomas of the paranasal sinuses and nasal cavity according to decade of radiation treatment.
  • METHODS AND MATERIALS: Between 1960 and 2005, 127 patients with sinonasal carcinoma underwent radiotherapy with planning and delivery techniques available at the time of treatment.
  • Nineteen patients (15%) received chemotherapy.
  • The most common histology was squamous cell carcinoma (83 patients).
  • There were no significant differences in any of these endpoints with respect to decade of treatment or radiotherapy technique (p > 0.05, for all).
  • CONCLUSION: Although we did not detect improvements in disease control or overall survival for patients treated over time, the incidence of complications has significantly declined, thereby resulting in an improved therapeutic ratio for patients with carcinomas of the paranasal sinuses and nasal cavity.
  • [MeSH-major] Nasal Cavity. Nose Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiation Injuries / prevention & control. Radiotherapy / adverse effects. Radiotherapy / trends. Radiotherapy, Conformal / adverse effects. Radiotherapy, Intensity-Modulated / adverse effects. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459609.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, Hoffman HT: Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience. Int J Radiat Oncol Biol Phys; 2005 Oct 1;63(2):410-21
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
  • PURPOSE: To review the University of Iowa experience with intensity-modulated radiotherapy (IMRT) in the treatment of head-and-neck squamous cell carcinoma.
  • METHODS AND MATERIALS: From October 1999 to April 2004, 151 patients with head-and-neck squamous cell carcinoma were treated with IMRT for curative intent.
  • One patient was lost to follow-up 2 months after treatment and therefore excluded from analysis.
  • Of the remaining 150 patients, 99 were treated with definitive IMRT, and 51 received postoperative IMRT.
  • Sites included were nasopharynx, 5; oropharynx, 56; larynx, 33; oral cavity, 29; hypopharynx, 8; nasal cavity/paranasal sinus, 8; and unknown primary, 11.
  • None of the patients treated with postoperative IMRT received chemotherapy.
  • Of 99 patients who had definitive IMRT, 68 patients received concurrent cisplatin-based chemotherapy.
  • One patient received induction cisplatin-based chemotherapy, but no concurrent chemotherapy was given.
  • The prescribed doses to CTV1, CTV2, and CTV3 in the definitive cohort were 70-74 Gy, 60 Gy, and 54 Gy, respectively.
  • For high-risk postoperative IMRT, the prescribed doses to CTV1, CTV2, and CTV3 were 64-66 Gy, 60 Gy, and 54 Gy, respectively.
  • For intermediate-risk postoperative IMRT, the prescribed doses to CTV1, CTV2, and CTV3 were 60 Gy, 60 Gy, and 54 Gy.
  • The median time from treatment completion to local-regional recurrence was 4.7 months (range, 1.8 to 15.6 months).
  • Patients with oropharyngeal cancer did significantly better than patients with oral cavity and laryngeal cancer, with a 2-year local-regional control rate of 98%, compared with 78% for oral cavity cancer and 85% for laryngeal cancer (p = 0.005).
  • There was no significant difference in local-regional control for patients who received postoperative radiation or definitive radiation (p = 0.339) and for patients who had chemotherapy or not (p = 0.402).
  • More studies are necessary to further improve the outcomes of laryngeal cancer as well as oral cavity cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Iowa. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed. Treatment Failure. Universities

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168834.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Langova V, Mutsaers AJ, Phillips B, Straw R: Treatment of eight dogs with nasal tumours with alternating doses of doxorubicin and carboplatin in conjunction with oral piroxicam. Aust Vet J; 2004 Nov;82(11):676-80
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of eight dogs with nasal tumours with alternating doses of doxorubicin and carboplatin in conjunction with oral piroxicam.
  • OBJECTIVE: To determine the efficacy and toxicity of chemotherapy in the treatment of canine nasal tumours.
  • DESIGN: Retrospective clinical study PROCEDURE: Eight dogs with histologically confirmed nasal tumours were staged by means of complete blood count, serum biochemical analysis, cytological analysis of fine needle aspirate of the regional lymph nodes, thoracic radiographs and computed tomography scan of the nasal cavity.
  • All dogs were monitored for side effects of chemotherapy and evaluated for response to treatment by computed tomography scan of the nasal cavity after the first four treatments.
  • RESULTS: Complete remission was achieved in four dogs, partial remission occurred in two dogs and two had stable disease on the basis of computed tomography evaluation.
  • There was resolution of clinical signs after one to two doses of chemotherapy in all dogs.
  • CONCLUSIONS: This chemotherapy protocol was efficacious and well tolerated in this series of eight cases of canine nasal tumours.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dog Diseases / drug therapy. Nose Neoplasms / veterinary
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / veterinary. Administration, Oral. Animals. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / veterinary. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / veterinary. Dogs. Doxorubicin / administration & dosage. Drug Administration Schedule. Male. Osteosarcoma / drug therapy. Osteosarcoma / veterinary. Piroxicam / administration & dosage. Records as Topic / veterinary. Retrospective Studies. Tomography, X-Ray Computed / veterinary

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15977611.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 13T4O6VMAM / Piroxicam; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin
  •  go-up   go-down


18. Prasad ML, Busam KJ, Patel SG, Hoshaw-Woodard S, Shah JP, Huvos AG: Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract. Arch Pathol Lab Med; 2003 Aug;127(8):997-1002
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract.
  • We compare melanomas arising in 2 histologically different mucosa, the stratified oral squamous mucosa and pseudostratified sinonasal respiratory mucosa, to investigate the clinicopathologic influence of native mucosal histology on the tumor.
  • METHODS: Clinicopathologic features of 36 melanomas arising in the squamous mucosa of the oral cavity were compared with 59 melanomas arising in the sinonasal respiratory mucosa.
  • RESULTS: The median age of patients was 61 and 63 years for oral and sinonasal melanomas, respectively, with the squamous and respiratory mucosa covering the maxilla being most frequently involved (68.7% and 66%, respectively).
  • Sinonasal melanoma showed vascular and deep tissue invasion more frequently than oral melanoma; however, no significant difference in disease-specific survival was noted (median survival, 2.8 years vs 3.0 years; 5-year survival, 37% vs 35%, respectively).
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Melanoma / pathology. Mouth Mucosa / pathology. Mouth Neoplasms / pathology. Nose Neoplasms / pathology. Respiratory Mucosa / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Nasal Mucosa / drug effects. Nasal Mucosa / pathology. Nasal Mucosa / surgery. Neoplasm Invasiveness / pathology. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery


19. El Ghelbazouri N, Afifi Y, Benameur H, Bella A, Elhallaoui Y, Kettani F, Aït Ourhrouil M, Senouci K, Hassam B: [Oral verrucous carcinoma and human papillomavirus infection]. Ann Dermatol Venereol; 2007 Aug-Sep;134(8-9):659-62
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oral verrucous carcinoma and human papillomavirus infection].
  • [Transliterated title] Carcinome verruqueux buccal et infection à papillomavirus.
  • BACKGROUND: Verrucous carcinoma of the oral cavity is a clinical variant of squamous cell carcinoma.
  • PATIENTS AND METHODS: A 72 year-old woman with a history of actinic cheilitis consulted for a bulky tumour of the lips and palate.
  • Clinical examination revealed a highly infiltrated labial tumour vegetating and budding, with a thick edge.
  • Biopsy samples from both sites indicated well-differentiated veruccous epidermoid carcinoma with chorionic infiltration.
  • The central facial scan showed involvement of the nasal fossae, soft palate and lips with lysis of the upper maxilla arcade and the osseous palate.
  • The patient died a few days before the start of preoperative chemotherapy following severe deterioration of her general state.
  • DISCUSSION: Verrucous carcinoma is an authentic well-differentiated low-grade cancer.
  • Diagnosis is based on histological examination.
  • Management and treatment are not codified but surgery remains the treatment of choice and relapse is common in the case of locoregional involvement.
  • [MeSH-major] Carcinoma, Verrucous / pathology. Human papillomavirus 16 / isolation & purification. Mouth Neoplasms / pathology. Papillomavirus Infections / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925690.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Ejaz A, Wenig BM: Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis. Adv Anat Pathol; 2005 May;12(3):134-43
Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis.
  • Sinonasal undifferentiated carcinoma (SNUC) is an uncommon, highly aggressive, and clinicopathologically distinctive carcinoma of uncertain histogenesis.
  • Adjunct analyses (eg, immunohistochemistry, electron microscopy, and molecular biologic studies) are often required in the diagnosis of SNUC and in differentiating it from other undifferentiated malignant neoplasms.
  • The treatment of SNUC includes aggressive multimodality therapy, including surgical resection and adjuvant therapy (ie, radiotherapy, chemotherapy).
  • The prognosis associated with SNUC is poor, and death due to disease often occurs within short periods following the diagnosis.
  • We believe that the histologic definition of SNUC can be expanded to include tumors with limited differentiated foci (ie, squamous cell differentiation) predicated on the caveats that the clinical parameters (ie, rapidly enlarging and destructive sinonasal lesions) and the majority of the histologic findings (ie, undifferentiated pleomorphic cell population) match those features that have heretofore defined SNUC.
  • The presence of squamous cell differentiation would correlate to origin in the Schneiderian epithelium, thereby conferring an ectodermal derivation to these tumors.
  • Irrespective of its cell of origin and perhaps even in the face of differentiated foci in limited parts of the tumor, given its rather unique clinicopathologic characteristics, this tumor should be identified and classified as SNUC, thereby differentiating it from the other specific types of sinonasal carcinomas and nonepithelial malignant tumors.
  • [MeSH-major] Carcinoma / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma, Neuroendocrine / pathology. Diagnosis, Differential. Esthesioneuroblastoma, Olfactory / pathology. Humans. Lymphoma, T-Cell, Cutaneous / pathology. Male. Melanoma / pathology. Middle Aged. Nasal Cavity / pathology. Nose Neoplasms / pathology. Prognosis. Rhabdomyosarcoma / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900114.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


21. Porceddu S, Martin J, Shanker G, Weih L, Russell C, Rischin D, Corry J, Peters L: Paranasal sinus tumors: Peter MacCallum Cancer Institute experience. Head Neck; 2004 Apr;26(4):322-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purpose of this study was to evaluate the local control, pattern of recurrence, overall survival, and prognostic factors of patients with squamous cell carcinoma (SCC), adenocarcinoma, and undifferentiated carcinoma of the paranasal sinuses (PNS) and nasal cavity (NC) presenting to our center for curative treatment over a 10-year period.
  • METHODS: Between 1991 and 2000, 60 patients with SCC (n = 32), adenocarcinoma (n = 25), and undifferentiated carcinoma (n = 3) of the PNS or NC were identified.
  • Forty patients received surgery and postoperative radiotherapy, four surgery alone; 11, radiotherapy alone; three radical radiotherapy after surgical recurrence; one, chemoradiotherapy and surgery; and one, induction chemotherapy followed by radiotherapy.
  • [MeSH-major] Carcinoma / mortality. Nasal Cavity / pathology. Nose Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Australia / epidemiology. Blindness / etiology. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Nervous System Neoplasms / secondary. Orbital Neoplasms / secondary. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • Genetic Alliance. consumer health - Sinus cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc.
  • (PMID = 15054735.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kim CH, Song KS, Kim KS, Kim JY, Lee BJ, Lee JG, Yoon JH: Sulindac sulfide-induced apoptosis in sinonasal cancer cells. Acta Otolaryngol; 2005 Feb;125(2):201-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: These results demonstrate that sulindac sulfide can induce cell death in maxillary cancer cells, and that sulindac sulfide-induced apoptosis is related to the extracellular signal-regulated kinase/p38 MAPK-caspase 3 signaling pathway.
  • Squamous cell carcinoma accounts for most sinonasal cancers.
  • However, little is known regarding the biochemical mechanism(s) of cell death in sinonasal cancers.
  • Recently, human epidemiological and clinical intervention studies have indicated that sulindac, a non-steroidal anti-inflammatory drug, exhibits chemopreventive activity in colorectal cancer.
  • In this study, we aimed to investigate whether sulindac sulfide can induce apoptosis in sinonasal cancer cells and what type of molecular mechanisms induces the death of sinonasal cancer cells.
  • The degree of cell death was determined by means of a fluorescence-activated cell scan and the signal transduction pathway for cell death was examined.
  • RESULTS: Human nasal cavity cancer cells treated with sulindac sulfide underwent cell death, and the induction of apoptosis occurred in a dose-dependent manner.
  • Moreover, sulindac sulfide-induced apoptosis was abolished by treatment with the caspase inhibitor Z-VAD-fmk and the mitogen-activated protein kinase (MAPK) inhibitors PD98059 and SB203580.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Apoptosis / drug effects. Carcinoma, Squamous Cell / drug therapy. Paranasal Sinus Neoplasms / drug therapy. Sulindac / analogs & derivatives. Sulindac / pharmacology. Sulindac / therapeutic use
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / administration & dosage. Amino Acid Chloromethyl Ketones / pharmacology. Caspase Inhibitors. Flavonoids / administration & dosage. Flavonoids / pharmacology. Fluorescence. Humans. Imidazoles / administration & dosage. Imidazoles / pharmacology. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Mitogen-Activated Protein Kinases / metabolism. Pyridines / administration & dosage. Pyridines / pharmacology. Signal Transduction / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880954.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Amino Acid Chloromethyl Ketones; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Caspase Inhibitors; 0 / Flavonoids; 0 / Imidazoles; 0 / Pyridines; 0 / SB 203580; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 184SNS8VUH / Sulindac; 6UVA8S2DEY / sulindac sulfide; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


23. Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M: Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg; 2009 Dec;135(12):1219-24
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: All patients with biopsy-proved malignant neoplasm of the sinonasal region who were treated with endoscopic resection between 1992 and 2007 were included in the study, and their charts were reviewed for demographics, histopathologic findings, treatment details, and outcome.
  • Of the 120 patients, 41% presented with previously untreated disease, 46% presented with persistent disease that had been partially resected, and 13% presented with recurrent disease after prior treatment.
  • The most common site of tumor origin was the nasal cavity (52%), followed by the ethmoid sinuses (28%).
  • However, the T-stage distribution was significantly different between the EEA group and the CEA group.
  • The most common tumor types were esthesioneuroblastoma (17%), sarcoma (15%), adenocarcinoma (14%), melanoma (14%), and squamous cell carcinoma (13%).
  • Other, less common tumors included adenoid cystic carcinoma (7%), neuroendocrine carcinoma (4%), and sinonasal undifferentiated carcinoma (2%).
  • Of the 120 patients, 50% were treated with surgery alone, 37% received postoperative radiation therapy, and 13% were treated with surgery, radiation therapy, and chemotherapy.
  • With a mean follow-up of 37 months, 18 patients (15%) experienced local recurrence, with a local disease control of 85%.
  • Our results suggest that, in well-selected patients and with appropriate use of adjuvant therapy, endoscopic resection of sinonasal cancer results in acceptable oncologic outcomes.
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Craniotomy. Disease-Free Survival. Esthesioneuroblastoma, Olfactory / surgery. Ethmoid Sinus. Female. Humans. Male. Melanoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Nose Neoplasms / mortality. Nose Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026819.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Li LL, Liu HG, Piao YS, He CY, Zhou Q, Zhang Y: [Clinicopathologic study of malignant tumors in head and neck region complicated by fungal infection]. Zhonghua Bing Li Xue Za Zhi; 2010 Aug;39(8):508-12
MedlinePlus Health Information. consumer health - Sinusitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumors in such cases included leukemia (n = 7) and nasopharyngeal carcinoma (n = 1).
  • These patients had history of chemotherapy/radiotherapy or antibiotics usage.
  • The remaining 13 cases of fungal infection often affected necrotic tumor tissue in nasal cavity, paranasal sinuses, pharynx, larynx and palate.
  • On the other hand, Aspergillus and Candida are the commonest fungi found in the necrotic tumor tissue.
  • Pathologic examination remains the hallmark in confirming the diagnosis and fungal typing.
  • [MeSH-minor] Adolescent. Adult. Aged. Antifungal Agents / therapeutic use. Aspergillosis / drug therapy. Aspergillosis / microbiology. Aspergillosis / pathology. Aspergillus / isolation & purification. Candida / isolation & purification. Candidiasis / drug therapy. Candidiasis / microbiology. Candidiasis / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / microbiology. Carcinoma, Squamous Cell / pathology. Child. Female. Follow-Up Studies. Humans. Lymphoma, Extranodal NK-T-Cell / drug therapy. Lymphoma, Extranodal NK-T-Cell / microbiology. Lymphoma, Extranodal NK-T-Cell / pathology. Male. Middle Aged. Retrospective Studies. Young Adult. Zygomycosis / drug therapy. Zygomycosis / microbiology. Zygomycosis / pathology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21055027.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


25. Day TA, Beas RA, Schlosser RJ, Woodworth BA, Barredo J, Sharma AK, Gillespie MB: Management of paranasal sinus malignancy. Curr Treat Options Oncol; 2005 Jan;6(1):3-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignancies of the nasal cavity and paranasal sinuses represent a wide spectrum of histologies, tissues of origin, and anatomic primary sites.
  • The inherent difficulty in generalizing treatment approaches is obvious, given the numerous variables associated with the broadly-based term, paranasal sinus malignancy (PNSCa).
  • Nevertheless, the majority of epithelial and salivary malignancies of this region (ie, squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, sinonasal undifferentiated carcinoma, and esthesioneuroblastoma) require surgical intervention as part of any treatment regimen.
  • Nonepithelial malignancies, including the wide variety of sarcomas arising in this region, most commonly require multimodality treatment including chemotherapy, radiation, and/or surgery for definitive treatment.
  • Moreover, the proximity of the nasal cavity and paranasal sinuses to structures including the orbit, dura, brain, cranial nerves, and carotid arteries mandates careful radiologic and neurologic evaluations throughout the course of the disease.
  • However, additional clinical trials are necessary to systematically evaluate the locoregional control, organ-preservation strategies, and survival related to the variety of treatments currently available.
  • [MeSH-major] Carcinoma / surgery. Melanoma / surgery. Paranasal Sinus Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Age Factors. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diet. Humans. Life Style. Prognosis. Radiotherapy, Adjuvant. Reconstructive Surgical Procedures

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):486-91 [12243826.001]
  • [Cites] Head Neck. 1995 Jul-Aug;17(4):303-11 [7672971.001]
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Med Pediatr Oncol. 1999 Oct;33(4):362-71 [10491544.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):335-41 [14716769.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):219-23 [10439167.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):371-6 [11859210.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):948-55 [15313865.001]
  • [Cites] Head Neck Surg. 1980 May-Jun;2(5):410-9 [7364592.001]
  • [Cites] Am J Otolaryngol. 2004 May-Jun;25(3):162-6 [15124164.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1157-62 [11583200.001]
  • [Cites] Oral Oncol. 2002 Jul;38(5):450-9 [12110339.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 15;128(2):130-6 [11463451.001]
  • [Cites] Laryngoscope. 2002 Oct;112(10):1871-6 [12368633.001]
  • [Cites] Oncology (Williston Park). 2000 Nov;14(11A):163-94 [11195409.001]
  • [Cites] Otolaryngol Clin North Am. 1995 Dec;28(6):1239-57 [8927395.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Jul;129(1):77-84 [12869921.001]
  • [Cites] Otolaryngol Clin North Am. 2004 Apr;37(2):473-87 [15064075.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):751-8 [12117328.001]
  • [Cites] Nature. 1987 Oct 15-21;329(6140):645-7 [3657988.001]
  • [Cites] Am J Rhinol. 2002 Jul-Aug;16(4):221-7 [12222948.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):158-68 [12694834.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Mar;3(2):84-9 [2031888.001]
  • [Cites] Am J Rhinol. 2002 Sep-Oct;16(5):281-6 [12422974.001]
  • [Cites] Stereotact Funct Neurosurg. 2004;82(2-3):84-9 [15305080.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):944-8 [12975266.001]
  • [Cites] Oncology (Williston Park). 1992 Jan;6(1):43-50; discussion 55-6 [1531603.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):361-9 [9607352.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):283-9 [9308929.001]
  • [Cites] Ear Nose Throat J. 2002 Aug;81(8):510-4, 516-7 [12199167.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):594-611 [12717245.001]
  • [Cites] Laryngoscope. 2000 Apr;110(4):635-40 [10764010.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):290-4 [11452937.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jul 1;136(1):53-7 [12165452.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1405-10 [11870186.001]
  • [Cites] Strahlenther Onkol. 2003 Apr;179(4):233-40 [12707712.001]
  • [Cites] Head Neck. 2004 Feb;26(2):136-44 [14762882.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):197-201 [11936913.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):204-13 [10623711.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jul;119(7):743-6 [8318204.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):147-54 [14697432.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Feb;47(1):9-15 [15100926.001]
  • [Cites] Acta Otorhinolaryngol Belg. 1996;50(1):19-24 [8669267.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2086-90 [14660907.001]
  • [Cites] Am J Surg Pathol. 1986 Mar;10 (3):192-202 [3953940.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5108-12 [8221646.001]
  • [Cites] Head Neck. 2004 May;26(5):435-41 [15122660.001]
  • [Cites] Head Neck. 2003 Oct;25(10):791-8 [12966502.001]
  • [Cites] Head Neck Surg. 1980 Jul-Aug;2(6):497-508 [6248488.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Acta Otorhinolaryngol Belg. 2000;54(2):221-32 [10892511.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Jan;3(1):17-21 [1705815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):823-9 [9369129.001]
  • [Cites] Epidemiology. 1998 Sep;9(5):518-24 [9730030.001]
  • [Cites] Eur J Nucl Med. 2001 Jul;28(7):816-21 [24770459.001]
  • [Cites] J Laryngol Otol. 1992 Dec;106(12):1063-6 [1487661.001]
  • [Cites] J Neurosurg. 1995 Jun;82(6):1002-10 [7760173.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Sep;128(9):1079-83 [12220216.001]
  • [Cites] Laryngoscope. 2002 Aug;112(8 Pt 1):1450-5 [12172261.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):208-10 [10439164.001]
  • [Cites] Head Neck. 1994 Nov-Dec;16(6):574-7 [7822181.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1101-7 [14652810.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Mar;129(3):334-7 [12622544.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1700-11 [10547542.001]
  • [Cites] Head Neck. 2004 Apr;26(4):322-30 [15054735.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):657-61 [1730116.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):255-64 [10421261.001]
  • [Cites] J Laryngol Otol. 1998 Jul;112(7):628-33 [9775291.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3743-9 [11268448.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Head Neck. 2004 Jul;26(7):584-93 [15229900.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):167-86 [15062368.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):147-57 [11936821.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Mar;120(3):387-90 [10064643.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):776-84 [12573765.001]
  • [Cites] Radiother Oncol. 1991 Jul;21(3):193-200 [1924855.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):932-7 [15333652.001]
  • [Cites] Cancer. 2003 Apr 25;99(2):105-12 [12704690.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1241-57, xi [11728944.001]
  • [Cites] Am J Epidemiol. 1994 Aug 15;140(4):340-9 [8059769.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):367-72 [12598339.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1597-604 [12459626.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1964-9 [12439163.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):101-7 [10361593.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Feb;47(1):1-8 [15100925.001]
  • [Cites] Minim Invasive Neurosurg. 2003 Oct;46(5):310-5 [14628249.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):318-31 [11567805.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • (PMID = 15610711.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


26. Lin CH, Liu NJ, Lee CS, Tang JH, Wei KL, Yang C, Sung KF, Cheng CL, Chiu CT, Chen PC: Nasogastric feeding tube placement in patients with esophageal cancer: application of ultrathin transnasal endoscopy. Gastrointest Endosc; 2006 Jul;64(1):104-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Obstructive symptoms may improve after radiotherapy and chemotherapy.
  • Nutrition support via a nasogastric tube (NG) or gastrostomy is very important during treatment.
  • The newly developed ultrathin endoscope (Olympus, GIF-N230, outer diameter: 6 mm) has a smaller diameter than the standard endoscope and can be introduced into the esophagus via the nasal cavity.
  • An ultrathin endoscope was used to advance the guidewire into the stomach via the nasal cavity.
  • Only one procedure failed because the esophageal lumen was completely occluded and the guidewire was not able to be passed through the obstructed site.
  • No procedure-related complications, such as bleeding or perforation, occurred.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Endoscopes, Gastrointestinal. Enteral Nutrition. Esophageal Neoplasms / therapy. Intubation, Gastrointestinal / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Deglutition Disorders / therapy. Endoscopy, Gastrointestinal. Equipment Design. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16813813.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Origitano TC, Petruzzelli GJ, Vandevender D, Emami B: Management of malignant tumors of the anterior and anterolateral skull base. Neurosurg Focus; 2002 May 15;12(5):e7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Biopsy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Craniotomy / methods. Ethmoid Bone. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nasal Cavity. Neuronavigation. Nose Neoplasms / drug therapy. Nose Neoplasms / pathology. Nose Neoplasms / radiotherapy. Nose Neoplasms / surgery. Preoperative Care. Radiotherapy, Adjuvant. Radiotherapy, Conformal. Surgical Flaps. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119905.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement